compounding glp-1 enforcement news Patients struggle as compounded access rapidly shrinks Court Dismisses Another Lawsuit Targeting

doi: 10.1039/C6MT00103C 149 LingS.-C.AlbuquerqueC

Husain M, et al

Medications like semaglutide and tirzepatide help address these underlying biological systems, giving patients another tool to support long-term health

Ozempic, already central in type 2 diabetes, has expanded with a new chronic kidney disease (CKD) label, reinforcing its role across the cardio-renal-metabolic spectrum. Wegovy Market Set to Expand as Obesity Treatment Demand Surges and GLP-1 Innovat The global Wegovy market is estimated to be valued at USD 10.96 Bn in 2025 and is expected to reach USD 31.51 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032